Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia

Annals of Hematology

Volumn 78, Issue 12, 1999, Pages 539-543

  Bazzan, Mario ^a   Tamponi, G ^a   Schinco, P ^a   Vaccarino, A ^a   Foli, C ^a   Gallone, G ^b   Pileri, A ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b MARIA VITTORIA HOSPITAL   (Italy)

Author keywords

Essential thrombocythemia; Life expectancy; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BUSULFAN; DIPYRIDAMOLE; FICLOPIDINE; HYDROXYUREA; INDOBUFEN; INTERFERON; PIPOBROMAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DEATH; DIABETES MELLITUS; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; ONSET AGE; PRIORITY JOURNAL; SMOKING; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS;

EID: 0033436293     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050555     Document Type: Article

References (32)

1. Murphy S, Illand H, Rosenthal DS, Laszlo J (1986) Essential thrombocythaemia: an interim report from the Polycythaemia Vera Study Group. Semin Hematol 23:177-182
2. Schafer AI (1991) Essential thrombocythemia. Progr Hemost Thromb 10:69-96
3. Michiels JJ (1996) The myeloproliferative disorders. A historical appraisal and personal experiences. Leuk Lymphoma 22:1-14
4. Rozman C, Giralt M, Feliu E, Ribio D, Cortes MT (1991) Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 67:2658-2663
5. Hehlmann R, Jahn M, Baumann B, Copcke W (1988) Essential thrombocythaemia. Clinical characteristics and course of 61 cases. Cancer 61:2487-2496
6. Schafer AI (1984) Bleeding and thrombosis in myeloproliferative disorders. Blood 64:1-12
7. Mitus AJ, Barbui T, Shulman LN, Rosenthal D, Viero P, Cortellazzo S, Shafer AI (1990) Hemostatic complications in young patients with essential thrombocythemia. Am J Med 88:371-375
8. Cortellazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythaemia. J Clin Oncol 8:556-562
9. Colombi M, Radaelli F, Zocchi L, Maiolo A (1991) Thrombotic and haemorrhagic complications in essential thrombocythaemia. Cancer 67:2926-2930
10. Griesshammer M, Bangerter M, van Vliet HH, Michiels JJ (1997) Aspirin in essential thrombocythaemia: status quo and quo vadis. Semin Thromb Haemost 23:371-377
11. Van Genderen PJ, Mulder PG, Waleboer M, Van de Moesdijk D, Michiels JJ (1997) Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol 97:179-184
12. Van Genderen PJ, Michiels JJ (1994) Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Med 23:73-77
13. Bellucci S, Janvier M, Tobelern G, Flandrin G, Charpak Y, Berger R, Boiron M (1986) Essential thrombocythaemia. Clinical, evolutionary and biological data. Cancer 58:2440-2447
14. Chistolini A, Mazzucconi MG, Ferrari A, La Verde G, Ferrazza G, Dragoni F, Vitale A, Arcieri R, Mandelli F (1990) Essential thrombocythaemia: retrospective study on the clinical course of 100 patients. Haematologica 75:537-540
15. Vadher BD, Machin SJ, Patterson KJ, Sukhu C, Walker H (1993) Life-threatening thrombotic and haemorrhagic problems associated with silent myeloproliferative disorders. Br J Haematol 85:213-216
16. Watson K, Key N (1993) Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol 83:198-203
17. Tefferi A, Silverstein MN, Hoagland HC (1995) Primary thrombocythemia. Semin Oncol 22:334-340
18. Geller SA, Shapiro E (1982) Acute leukemia as a natural sequel to primary thrombocythaemia. Am J Clin Pathol 77:352-356
19. Pearson TC (1991) Primary thrombocythaemia: diagnosis and management. Br J Haematol 78:145-148
20. Word Health Organization (1971) Ischaemic heart disease register: report of the Fifth Working Group, including a second revision of the operating protocol, Copenhagen, Denmark, April 26-29
21. National Institute of Neurological Disorders and Stroke (1990) Special report: classification of cerebrovascular diseases. III. Stroke 21:637-676
22. Lahuerta-Palacios JJ, Bornstein R, Fernandez-Debora F, Gutierrez-Rivas E, Ortiz MJ, Larregla S, Calandre L, Montero-Castillo J (1988) Controlled and uncontrolled thrombocytosis. Cancer 61:1207-1212
23. Cortellazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barhui T (1995) Hydroxyurea for patients with essential thrombocythaemia at a high risk of thrombosis. N Engl J Med 332:1131-1136
24. Michiels JJ (1999) Normal life expectancy and thrombosis-free survival in aspirin-treated essential thrombocythaemia. Clin Appl Thromb Haemost (in press)
25. Pedrides PE, Beykirch MK, Trapp OM (1998) Anagrelide, a novel platelet-lowering option in essential thrombocythaemia: treatment experiences in 48 patients in Germany. Eur J Haematol 61:71-76
26. Barbui T, Finazzi G, Dupuy E, Kiladjian JJ, Briere J (1996) Treatment strategies in essential thrombocythemia. Leuk Lymphoma 22 [Suppl 1]: 149-160
27. Michiels JJ, Van Genderen PJ, Pruidemans J, Van Vliet HH (1996) Erythromelalgic, thrombotic and haemorrhagic manifestations in 50 cases of thrombocythaemia. Leuk Lymphoma 22 [Suppl 1]: 47-56
28. Barbui T, Finazzi G (1999) Clinical parameters for determining when and when not to treat essential thrombocythemia. Semin Hematol 36 [Suppl 2]: 14-18
29. Sterkers J, Preudhomme V, Lai Yl, Demory JL, Caulier MT, Wattel E, Bordessoulle D, Bauters F, Fenaux P (1998) Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythaemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 91:616-622
30. Silverstein MN, Tefferi A (1999) Treatment of essential thrombocythemia with anagrelide. Semin Hematol 36 [Suppl 2]: 23-25
31. Lengfelder E, Griesharnmer M, Hehlmann R (1996) Interferon alpha in the treatment of essential thrombocythaemia. Leuk Lymphoma 22 [Suppl 1]: 135-142
32. Tefferi A, Silverstein MM, Petit RM, Mesa RA, Solberg LA (1997) Anagrelide as a new platelet-lowering agent in essential thrombocythaemia: mechanism of action, efficacy, toxicity, current indications. Semin Haemost 23:379-383